FcR gamma chain does not replace CD3[zeta] chain in CD3[zeta]-deficient T lymphocytes of patients with gastric adenocarcinoma

Defective CD3[zeta] chain expression has been reported in T lymphocytes of patients with inflammatory diseases, such as systemic lupus erythematosus or osteoarthritis, and with cancer. In lupus, the absent CD3[zeta] chain is replaced by the FcR gamma chain, rendering the T cells hyper responsive. Ho...

Full description

Saved in:
Bibliographic Details
Published in:Molecular immunology 2007-03, Vol.44 (9), p.2400-2405
Main Authors: Lopez-Santalla, Mercedes, Krishnan, Sandeep, Valeri, Anna P, Aguilera-Montilla, Noemi, Fisher, Carolyn U, Perez-Blas, Mercedes, Gutierrez-Calvo, Alberto, Lasa, Inmaculada, Granell-Vicent, Javier, Tsokos, George C, Martin-Villa, Jose M
Format: Article
Language:English
Subjects:
Herpesvirus
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Defective CD3[zeta] chain expression has been reported in T lymphocytes of patients with inflammatory diseases, such as systemic lupus erythematosus or osteoarthritis, and with cancer. In lupus, the absent CD3[zeta] chain is replaced by the FcR gamma chain, rendering the T cells hyper responsive. However, there are no data on T lymphocytes from patients with cancer. In this study, the presence of the FcR gamma chain and its associated kinase, Syk, was analysed in patients with gastric adenocarcinoma and healthy subjects. Western blot and immunoprecipitation experiments were carried out with total cell or lipid raft extracts from fresh peripheral blood mononuclear cells or T lymphocytes, and Herpesvirus saimiri-derived T-cell lines (of blood or tissue origin). Our results revealed that the absent CD3[zeta] chain in cancer T lymphocytes was not replaced by FcR gamma either in fresh T cells or T-cell lines, in contrast to lupus T cells. This altered expression of signalling molecules in T lymphocytes of cancer patients, would explain their low proliferative capacity. Our T-cell lines represent tools to unveil the signalling abnormalities of cancer T lymphocytes.
ISSN:0161-5890
DOI:10.1016/j.molimm.2006.10.012